an individualized mRNA vaccine from Merck and Moderna, known as V940 (mRNA-4157), paired with pembrolizumab to keep high-risk melanoma from returning. Phase-2 results, published in the New England Journal of Medicine and extended in longer follow-up, found the combo cut the risk of recurrence or death by about 44% and showed roughly 2.5–3-year recurrence-free survival of ~75% vs ~56% on the drug alone. Phase-3 is where it gets proved or disproved. Steve signs anyway.
In New York, Memorial Sloan Kettering surgeon-scientist Vinod Balachandran walks the pancreatic unit’s corridor. Early results, reported in Nature and extended in follow-up, showed a personalized mRNA vaccine (autogene cevumeran) generating long-lived CD8 T-cell responses that correlated with delayed recurrence—a rare few extra ticks against pancreatic cancer’s brutal clock. A randomized trial is underway to test whether that immune footprint drives the clinical benefit. The cancer trials show what’s possible. But the platform’s reach is already slipping into ordinary medicine.
Beyond cancer, the platform is edging into routine care: in June 2025 the Food and Drug Administration expanded Moderna’s RSV shot to at-risk adults under 60; an mRNA flu program cleared Phase-3 in older adults, filings pending; and a CMV vaccine—targeting the leading infectious cause of birth defects—is now in pivotal trials. These aren’t conference posters. They’re edging into clinics.
And yet, back in Washington, another kind of clock is being taken apart.
In June, Kennedy dismissed all 17 members of the CDC’s vaccine advisory committee and began seating new members, including figures openly skeptical of routine vaccination. The reconstituted committee meets in September to revisit recommendations, including COVID-19 and RSV. The pattern is clear: remake the committee, constrain the products, rewrite the playbook — the playbook that decides who gets vaccinated, and who doesn’t.
Then, on Aug.5, the Biomedical Advanced Research and Development Authority announced it would wind down mRNA vaccine development, terminating or de-scoping 22 projects (about $500 million) and pledging no new mRNA initiatives—moves hospital leaders and researchers say will chill next-gen respiratory vaccines and spill into adjacent RNA therapeutics. Even where late-stage contracts limp on, the signal to the field is unmistakable. After that first mention, researchers simply call it the agency that turned off the tap.
That’s the arc: Kennedy surrounds himself with anti-vax and anti-mRNA voices, purges the advisory guardrails, and chokes the funding lines—an attempt to stop mRNA research and shrink its clinical footprint to the smallest possible lane. The science didn’t change last week. The politics did.
For Andrew, that means leaving the mask in its drawer. For Steve, it’s penciling another scan into the calendar. For families in wards and waiting rooms, that time is everything. A quiet monitor, a penciled date, a deeper breath.
mRNA doesn’t stop the clock. It buys it—days out of the ICU, seasons between scans, pregnancies without CMV.
Keep the hands moving.